Gentamicin-associated acute kidney injury

QJM: An International Journal of Medicine

Volumn 102, Issue 12, 2009, Pages

  Selby, Nicholas M ^a   Shaw, Susan ^a   Woodier, Nicholas ^a   Fluck, Richard J ^a   Kolhe, Nitin V ^a  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GENTAMICIN; NONSTEROID ANTIINFLAMMATORY AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE ABDOMEN; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPOTENSION; INCIDENCE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PYELONEPHRITIS; RISK FACTOR; SEPSIS; URINARY TRACT INFECTION; URINE VOLUME; ACUTE KIDNEY FAILURE; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; CRITICAL ILLNESS; HOSPITALIZATION; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; GENTAMICINS; HOSPITAL MORTALITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, ACUTE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 77950550024     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp143     Document Type: Article

References (23)

1. Matzke GR, Lucarotti RL, Shapiro HS. Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol 1983; 3:11-7.
2. Raveh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, Yinnon AM. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. Qjm 2002; 95:291-7.
3. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549-55.
4. Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998; 13:735-9.
5. Prins JM, Weverling GJ, de Blok K, van Ketel RJ, Speelman P. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 1996; 40:2494-9.
6. Fujita K, Sayama T, Abe S, Murayama T, Tashiro H. Agedependent aminoglycoside nephrotoxicity. J Urol 1985; 134:596-7.
7. Weir BA, Mazumdar DC. Aminoglycoside nephrotoxicity following single-dose cystoscopy prophylaxis. Ann Pharmacother 1994; 28:199-201.
8. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39:650-5.
9. Kumin GD. Clinical nephrotoxicity of tobramycin and gentamicin. A prospective study. JAMA 1980; 244:1808-10.
10. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312:338-45.
11. Schentag JJ, Plaut ME, Cerra FB. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother 1981; 19:859-66.
12. Smith CR, Lipsky JJ, Laskin OL, Hellmann DB, Mellits ED, Longstreth J, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302:1106-9.
13. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-12.
14. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int 2008; 73:538-46.
15. Cooke RP, Grace RJ, Gover PA. Audit of once-daily dosing gentamicin therapy in neutropenic fever. Int J Clin Pract 1997; 51:229-31.
16. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001; 52(Suppl. 1):35S-43S.
17. Shrimpton SB, Milmoe M, Wilson AP, Felmingham D, Drayan S, Barrass C, et al. Audit of prescription and assay of aminoglycosides in a UK teaching hospital. J Antimicrob Chemother 1993; 31:599-606.
18. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
19. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17:1085-92.
20. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16:3365-70.
21. Eltahawy AT, Bahnassy AA. Aminoglycoside prescription, therapeutic monitoring and nephrotoxicity at a university hospital in Saudi Arabia. J Chemother 1996; 8:278-83.
22. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352-7.
23. Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003; 114:194-8.